Italia markets close in 3 hours 43 minutes
FTSE MIB
34.512,28 -312,73 (-0,90%) Dow Jones
39.806,77 -196,82 (-0,49%) Nasdaq
16.794,88 +108,91 (+0,65%) Nikkei 225
38.946,93 -122,75 (-0,31%) Petrolio
78,45 -1,35 (-1,69%) Bitcoin EUR
65.605,54 +3.869,29 (+6,27%)
NVCR Jan 2025 30.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 01:20PM EDT. Mercato aperto.
| Chiusura precedente | 4,6000 |
| Aperto | 4,1000 |
| Denaro | 0,0000 |
| Lettera | 0,0000 |
| Prezzo d'esercizio | 30,00 |
| Scadenza | 2025-01-17 |
| Min-Max giorno | 4,1000 - 4,6000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1,21k |
GlobeNewswireZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
© 2024 Yahoo. Tutti i diritti riservati.